Welcome to our dedicated page for Prelude Therapeutics news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics stock.
Prelude Therapeutics Incorporated (Nasdaq: PRLD) is a clinical-stage precision oncology company, and its news flow reflects the progress and risks of early-stage cancer drug development. Company announcements frequently cover updates on highly selective SMARCA2 degraders, oral KAT6A degraders, a mutant selective JAK2V617F JH2 inhibitor program for myeloproliferative neoplasms, and mutant CALR-targeted degrader antibody conjugates (DACs).
Investors and researchers following PRLD news can expect regular reports on clinical trial milestones, such as Phase 1 dose-escalation progress for PRT7732, completion of Phase 1 studies for PRT3789, and plans for Phase 2 combinations with agents like pembrolizumab. Press releases also summarize preclinical data presented at major medical meetings, including the American Association for Cancer Research, the American Society of Hematology, European Hematology Association, and other oncology-focused conferences.
Prelude’s news often highlights strategic portfolio decisions, for example prioritizing KAT6A and JAK2V617F programs, pausing further clinical development of certain SMARCA2 programs, and expanding collaborations. Announcements have detailed an exclusive option agreement with Incyte for the JAK2V617F program and an expanded collaboration with AbCellera Biologics around degrader payloads for precision DACs.
In addition, PRLD news includes quarterly financial results, cash runway commentary, and governance updates such as board appointments and leadership changes. For those tracking precision oncology and targeted protein degradation, this news stream provides insight into Prelude’s evolving pipeline, partnership activity, and regulatory and listing developments. Bookmark this page to review the latest earnings releases, scientific data disclosures, and corporate updates related to Prelude Therapeutics stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.